ViaDerma Inc (EM) (VDRM)

Well taki for once I absolutely agree with you...it's time

READ THIS CAREFULLY.OTIKO IS NEXT.READ ALL BOLD SPOTS.
SueWallSt is a nationally recognized shareholder rights firm. Over the past 20 years, the firm has secured hundreds of millions of dollars for aggrieved shareholders. Ranked in ISS Top 50 for seven consecutive years.

Frequently Asked Questions About the BTGO Lawsuit

Q: What specific misstatements does the BTGO lawsuit allege? A: The complaint alleges BitGo made materially false or misleading statements regarding its financial projections, business resilience, and the severity of risks posed by declining digital asset prices. When the true financial picture was revealed, the stock price declined sharply.

Q: How much did BTGO stock drop? A: Shares fell approximately 15.71%, a decline of $1.43 per share, after the Company disclosed a $14.8 million net loss for 2025 instead of the projected profit. Shares fell an additional 17.2% after Q1 2026 results showed a $60.7 million loss.

Q: What do BTGO investors need to do right now? A: Gather brokerage records including purchase dates, share quantities, and prices paid. Contact SueWallSt for a free, no-obligation evaluation at jlevi@SueWallSt.com or (888) SueWallSt. No immediate action is required to remain eligible as a class member.

Q: What if I already sold my BTGO shares, can I still recover losses? A: Yes. Eligibility is based on when you purchased, not whether you still hold them. Investors who bought during the class period and sold at a loss may still participate.

Q: Do I need to go to court or give testimony? A: No. The overwhelming majority of class members never appear in court or give depositions. You submit a claim form to receive your portion of recovery.

Q: What does it cost me to participate? A: Nothing. Securities class actions are handled on a pure contingency basis. No upfront fees, no retainer, no out-of-pocket costs.

Q: Has SueWallSt handled similar cases before? A: Yes, including securities class actions involving revenue inflation, earnings guidance fraud, dividend misrepresentation, and executive misconduct across numerous industries.

CONTACT:
SueWallSt
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
33 Whitehall Street, 27th Floor
New York, NY 10004
jlevi@SueWallSt.com
Tel: (888) SueWallSt
Fax: (212) 363-7171

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/btgo-shareholder-alert-bitgo-holdings-inc-securities-class-action-lawsuit---investors-should-contact-suewallst-302803946.html

I THINK IT IS PASSED DUE FOR A LAWSUIT.IT IS TIME TO GET OTIKO IN JAIL,OR COMPLETELY BROKE.THINGS ARE EASY TO F HIM UP.READ THIS VERY RECENT SECURUTIES CLASS ACTION LAWSUIT.
READ ALL BOLD SPOTS.SHAREHOLDERS CAN COOK THIS BASTARD.AND WILL COST THEM NOTHING.OTIKO HAS TO GO DOWN.
WHERE OTIKO IS HEADED:::::1)JAIL TIME.2)BROKE.3)DIVORCE
https://investorshub.advfn.com/stock-market/NYSE/bitgo-BTGO/stock-news/98771348/btgo-shareholder-alert-bitgo-holdings-inc-secur
BTGO Shareholder Alert: BitGo Holdings, Inc. Securities Class Action Lawsuit - Investors Should Contact SueWallSt
June 18 2026 - 10:07AM
PR Newswire (US)
Alert
Print
Share On Facebook
Promise vs. Reality: BitGo Projected $3.5 Million in Net Income for 2025 but Delivered a $14.8 Million Net Loss

NEW YORK, June 18, 2026 /PRNewswire/ -- BitGo Holdings, Inc. (NYSE: BTGO) told investors one story in its January 2026 IPO documents. The numbers told another. Find out if you qualify to recover losses from BitGo's broken projections or contact Joseph E. Levi, Esq. at jlevi@SueWallSt.com or (888) SueWallSt.

SueWallSt.com

BitGo's Offering Documents estimated 2025 net income from operations between $3.2 million and $3.5 million. The actual result: a net loss of $14.8 million. That is a negative swing of approximately $18 million to $18.3 million from the top of the projected range. Shares, which debuted at $18.00 in the IPO, fell 15.71% on the day these results were disclosed, and fell an additional 17.2% after Q1 2026 results widened losses to $60.7 million. The lead plaintiff deadline is August 7, 2026.

The Promise

In the Registration Statement and Prospectus filed in January 2026, the Company laid out specific financial projections for the fiscal year just ending:

Estimated net income from operations between $3.2 million and $3.5 million
Digital Asset Sales revenue between $15,475.7 million and $15,522.3 million
An "expected increase" in total revenue driven by higher trading activity, expanded trading pairs, and a growing client base
A business with "strong and resilient" fundamentals that had produced "progressively increasing" trading activity since inception
Assets on Platform that had grown from $17.0 billion to a peak of $104.0 billion in just three years
These projections formed the basis on which investors purchased 11.8 million shares at $18.00 each, generating over $187.58 million in IPO proceeds.

The Reality

The actual 2025 results, disclosed on March 26, 2026, contradicted the IPO projections across every material dimension, the lawsuit contends:

Net loss of $14.8 million instead of projected income of $3.2 to $3.5 million
Digital Asset Sales margin collapsed to 0.21%, less than half of the prior year's 0.47%
Assets on Platform fell to $81.6 billion, a 9% year-over-year decrease from the trajectory highlighted in the IPO
Assets staked plummeted 51% year-over-year to $15.6 billion
Take rate compressed to 21 basis points for the full year
Management declined to provide Q1 2026 guidance with only five days remaining in the quarter
The Numbers: Promised vs. Actual

Metric

IPO Promise

Actual Result

FY 2025 Net Income

$3.2M to $3.5M profit

($14.8M) loss

Digital Asset Sales Margin

Prior year: 0.47%

0.21 %

Assets on Platform Trend

Peak of $104.0B (Sept 2025)

$81.6B (Dec 2025)

Q1 2026 Net Loss

No guidance provided

($60.7M)

The gap between promise and reality widened further in Q1 2026, when the Company reported a net loss of $60.7 million compared to $25.7 million in the prior year period, citing "weaker market conditions."

What the Lawsuit Alleges About the Gap

The complaint asserts that the Company's leadership understood the severity of digital asset price declines and their impact on revenue well before IPO investors received that information. The action claims the Offering Documents understated the scope of these risks while simultaneously projecting profitability and touting "strong and resilient" business fundamentals that allegedly lacked a reasonable basis.

"Companies that make specific promises to investors about future performance have an obligation to disclose known risks to those projections. When a company projects profitability in its IPO documents and delivers a multimillion-dollar loss driven by risks it characterized as manageable, serious questions arise about what was known at the time those projections were made." -- Joseph E. Levi, Esq.

Check if you can recover your investment losses from the BitGo IPO or call (888) SueWallSt.

LEAD PLAINTIFF DEADLINE: August 7, 2026

SueWallSt is a nationally recognized shareholder rights firm. Over the past 20 years, the firm has secured hundreds of millions of dollars for aggrieved shareholders. Ranked in ISS Top 50 for seven consecutive years.

Frequently Asked Questions About the BTGO Lawsuit

Q: What specific misstatements does the BTGO lawsuit allege? A: The complaint alleges BitGo made materially false or misleading statements regarding its financial projections, business resilience, and the severity of risks posed by declining digital asset prices. When the true financial picture was revealed, the stock price declined sharply.

Q: How much did BTGO stock drop? A: Shares fell approximately 15.71%, a decline of $1.43 per share, after the Company disclosed a $14.8 million net loss for 2025 instead of the projected profit. Shares fell an additional 17.2% after Q1 2026 results showed a $60.7 million loss.

Q: What do BTGO investors need to do right now? A: Gather brokerage records including purchase dates, share quantities, and prices paid. Contact SueWallSt for a free, no-obligation evaluation at jlevi@SueWallSt.com or (888) SueWallSt. No immediate action is required to remain eligible as a class member.

Q: What if I already sold my BTGO shares, can I still recover losses? A: Yes. Eligibility is based on when you purchased, not whether you still hold them. Investors who bought during the class period and sold at a loss may still participate.

Q: Do I need to go to court or give testimony? A: No. The overwhelming majority of class members never appear in court or give depositions. You submit a claim form to receive your portion of recovery.

Q: What does it cost me to participate? A: Nothing. Securities class actions are handled on a pure contingency basis. No upfront fees, no retainer, no out-of-pocket costs.

Q: Has SueWallSt handled similar cases before? A: Yes, including securities class actions involving revenue inflation, earnings guidance fraud, dividend misrepresentation, and executive misconduct across numerous industries.

CONTACT:
SueWallSt
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
33 Whitehall Street, 27th Floor
New York, NY 10004
jlevi@SueWallSt.com
Tel: (888) SueWallSt
Fax: (212) 363-7171

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/btgo-shareholder-alert-bitgo-holdings-inc-securities-class-action-lawsuit---investors-should-contact-suewallst-302803946.html

SOURCE SueWallSt.com


Copyright 2026 PR Newswire

Yes, it is becoming more apparent than ever that Otiko if a fucking pos and nothing more. He's living a great life while shareholders are left in the dark as to what the fuck is going on with the company. I would LOVE to see him in handcuffs if he is found guilty of stealing shareholder money.

I have seen ( 1 ) go to jail 4 less.

Selling  10 to buy space x????😂😂😂😂🤪🤪🤪🤪

Thought they shipped over a million of these?

Looking at the reviews https://www.trustpilot.com/review/viaderma.com there's only 7 from 500K sales?

Contact info is 4 Bahama Bend, 92118, Coronado, United States

Not a bad $2.7 million home / office a block from the ocean for the Dr. https://www.redfin.com/CA/Coronado/4-Bahama-Bnd-92118/home/6113475

It's far past due for the SEC to get involved and put an end to this BS. This house should be owned by the shareholders.

New styled website shows that over 500k+ units have been distributed…… I guess the good Dr is donating all these samples and not receiving any money for them in order to right the company and filings……
https://viaderma.com/

Time to file a complaint with the SEC and freeze his assets…..

13 now what not just hit the bid 😂😂😂😂😂😂😂

go away

Dr. Otiko will bring VDRM back!

At this pojnt I would consider it to be a positive sign if there was any solid evidence of any other person than Dr. Otiko being a part of VDRM.

I confirmed that it is NOT illegal per se to update shareholders while the company is on the Expert market. They are simply choosing not to provide any updates. We don't need detailed announcements, but a progress update would be appreciated. I sent them another email. Not holding my breath.

He has nothing to sell but more lies

Face Book CVS Walgreens It's all laughable

It has become apparent to me that IR knows nothing (I know others have said this before). Not sure why that is. I can only assume that they also do not communicate with Otiko very often. Who knows, maybe their not getting paid. Maybe there is simply nothing to report.

I would love to see it removed from my stock list as well. Every day I see a big red negative number and it's like getting hit on the top of the head with a stupid stick for falling for Otiko's bullshit to begin with. At this point, we could easily be asking the same questions next year at this time. I just wish he would man-up and have the professional courtesy to come out and tell us it's over so I can put it behind me.

Otiko, if you or any of your supposed new-hires are reading this thread....WTF ARE YOU DOING????? IT'S BEEN OVER A YEAR ON THE EXPERT MARKET. DO YOU UNDERSTAND THAT WE CAN'T TRADE THE STOCK??? EFFECTIVELY WE HAVE ALL LOST OUR MONEY!!!!! DO YOU GIVE A SHIT AT ALL????

Yep, more bs responses. The fact that Otiko isn't manning up and communicating what is happening is very disturbing and why these small companies are a crapshoot at best. The leadership drives companies forward, and it's clear as day that otiko is not a leader in any way, shape or form. I've seen the same shit from a bunch of other tiny companies over the years. These companies should never be allowed to go public until the president/CEO can demonstrate competency in running the company.

I just want to get it from showing up in my list of stocks each day.

LOL.THE GUY THAT WAS TALKING TO RICHIE.AND ALL WAS GOOD.AND FILINGS WOULD COME BACK IN JANUARY.LMAO

DeerBalls

Re: None

Saturday, December 27, 2025 8:09:41 PM

Post#
77160
of 77468
VDRM will be back, better than ever.....

ATTENTION TO ALL SHAREHOLDERS.IF YOU EVER SEE OTIKO AS A CEO ON A NEW COMPANY THAT TRADES PLEASE LET ME KNOW IMMEDIATELY.HIS NAME IS AS GOOD AS $HIT.HE IS FD FOR EVER RUNNING ANOTHER PUBLIC COMPANY.

THIS ANSWER YOU RECEIVED SAYS ALL YOU NEED TO KNOW.THIS THING WILL NEVER COME BACK TO TRADING IMO.
Here is the response I received on May 7th: I am really sorry I dont have anything new to tell you just yet. Unfortunately it is not as easy as just filing the missing statements because of the changes to the OTC with the introduction of the OTCIQ. Still working on a resolution.

On May 8th, I then sent the following email. To date I have not received a response:

Thank you for the response. I appreciate the acknowledgment and understand that the OTCIQ transition has added complexity beyond simply filing missing statements.

From a shareholder perspective, the continuing operational activity; including the updated website, VitaStem/SkinPass promotion, hiring efforts, and discussion of expansion opportunities, etc. suggests that the company continues to build the business despite the ongoing Expert Market situation. Because of that, many shareholders remain hopeful that the company ultimately intends to restore tradability and emerge in a stronger position.

My own view has been that management may be prioritizing the development of recurring revenues, potential retail distribution opportunities, stronger financial positioning, outside investment, and audited financials before taking steps toward returning to a fully tradable public status. Of course, I understand that this is only my interpretation and that the company may not yet be able to comment on specific plans or timing.

At this stage, however, the largest source of shareholder frustration appears to be the limited communication rather than the delay itself. Even occasional high-level updates acknowledging progress, challenges, or general intentions would likely go a long way toward maintaining shareholder confidence during this process.

Thank you again for your time and consideration.

On May 6th, I sent the following email to Rich:

I wanted to follow up on my previous email, as I did not receive a response.

Many long-term shareholders are becoming increasingly discouraged by the continued lack of communication regarding the company’s status and plans for resuming public trading. As the one-year anniversary of VDRM entering the Expert Market approaches, the silence has unfortunately created significant uncertainty among investors.

At the same time, shareholders continue to see signs that the company remains operational and active, including the updated website, ongoing product promotion, hiring efforts, and prior public comments regarding expansion opportunities. This visible business activity versus the absence of shareholder updates has made many investors unsure how to interpret the company’s direction moving forward.

I fully understand that management may not yet be in a position to disclose certain developments. However, even a general update or brief reassurance from Dr. Otiko or Investor Relations regarding the company’s intentions and progress would mean a great deal to shareholders who have remained supportive during this difficult period.

Thank you again for your time and consideration.

Here is the response I received on May 7th: I am really sorry I dont have anything new to tell you just yet. Unfortunately it is not as easy as just filing the missing statements because of the changes to the OTC with the introduction of the OTCIQ. Still working on a resolution.

IR part timers, Rich, is not even answering emails or calls anymore. What a complete disaster of a company through and through. If Otiko did scam us, I hope he rots in hell...soon. I'm holding out hope he's just a completely incompetent pos.

Come on Dr. Come up with another scam so we can bring this piece of $hit back to life….. has anyone heard anything from these? A holes do we still have a pulse?

TODAY IS BEEN MORE THAN A YEAR THAT THE SCAMBAG OTIKO PUT THE SHAREHOLDERS IN THE DARK FOR GOOD.BY ALLOWING THE POS COMPANY TO GO TO EXPERT MARKET.AND SHAFT ALL SHARE HOLDERS WITH SOME LOSING 6 FIGURE $$$
GOD IS WATCHING YOU OTIKO.VERY CLOSELY.NO ONE GETS AWAY LITTLE MAN.FOR DOING BAD TO PEOPLE.

Market Change 05/16/2025 VDRM Market change from Pink Limited to Expert Market

How do U run out when U never had it?

Dr. & family needed the $$ 4 a vacation

Website says sold out… OK SO WHERE’S THE MONEY? .. it must of been deposited in the same bank as the Nigerian sale

Maybe Dr. dirtbag can sell holy water and bring us back from the dead

Maybe Dubai bought it all 🤣

Looks like they’re sold out. Either they sold a ton or they haven’t made any yet???

Vitastem Sales Website:
https://store.getvitastem.com/

It appears it started around April 1.....

OTIKO SHAFTED MAJORLY ALL THE SHAREHOLDERS OF VDRM.I BELIEVE THERE ARE SOME GUYS HERE,THAT HAVE INVESTED 6 FIGURES IN THIS THING.

This is a factual statement

Dig into red flags in management behavior?

Really? These were all pointed out several times along the way....yall just chose to ignore and ridicule those pointing them out...

Wow somebody hit 10 and 12 appear on. The bid

Think they sold 4 cheap?

So what it could be 10 cents and I still can’t sell or buy a share… Dr Dirtbag should be ashamed of himself … his day will come ….

no respect should have never happened

10k on the bid at .0011

I like your thinking and you could be right. For now this is a totally dead, but not gone, investment.

While super frustrating, I would rather be illiquid for another 24 months and have them re-enter the market as a strong going concern with healthy debt levels, vs re-listing with the train wreck financials from the last update. I think we stand to make more by waiting, if in fact they’re able to get their act together. And I’ve got 70K tied up here so believe me I’m not happy about it. But I’ve come to terms with this having greater potential by getting stronger prior to relisting than rushing it. And for my emotional and financial health, my 70K is dead money at this point. If it happens to relist, fantastic. But I’m assuming the worst for now while hoping for better days in the future.

My take is that Otiko is in no hurry to get uplisted. If Otiko truly believes that Vitastem/SkinPass can scale to market, retail distribution is real, Africa expansion is real, funding is material, and that revenues could become substantial, then remaining public has potentially enormous upside for him personally because of the large number of shares he holds. Why would he pass on the opportunity to potentially make hundreds of millions of dollars? That being the case, one would think that restoring tradability would be a very high priority. While Otiko might be in no hurry to get uplisted, my theory is that he is waiting for recurring revenues, major retail rollout, stronger balance sheet, outside capital investment and audited financial statements. All of that could be baked into a reorganization of sorts that allows VDRM to emerge from the Expert Market in a much better positon. Yeah I know it's wishful thinking. If that is the case, we could be looking at another 6 to 12 to 18 months or longer.

Given that, until there is something to report, there is nothing to report. See you all in 6 months.

From ChatGPT about VDRM:

Here’s the reality of what’s going on with ViaDerma, Inc. (VDRM) — and I’ll be direct, because this situation is pretty common in microcap/OTC names.

---

# 🧭 1. What actually happened (delisting / “under review”)

VDRM hasn’t been “delisted” in the traditional sense (like being removed from NASDAQ). Instead:

* It has been moved to the **OTC Expert Market** ([GuruFocus][1])
* This typically happens when a company:

* **Fails to stay current with financial filings**
* Falls out of compliance with OTC reporting rules

👉 Key consequence:

* Shares become **extremely illiquid**
* Retail investors often **can’t buy** (only limited selling)
* Public information becomes **very limited**

This is why it *feels* like a delisting — but technically it’s a downgrade to a restricted market tier.

---

# 📊 2. Why they were pushed there

The biggest issue is straightforward:

* The company has had **overdue annual and quarterly reports** ([GuruFocus][1])
* There are **no consistent SEC filings available** ([Nasdaq][2])

That’s a major red flag in public markets.

Even the company itself admitted:

* They are **working to complete overdue reports**
* They are trying to get back into compliance ([GuruFocus][1])

---

# 🧪 3. Is the company dead?

Not necessarily — but it’s not in good shape either.

From their own updates:

* They claim to be **“fully operational”** ([GuruFocus][1])
* They’re still talking about:

* International shipments (e.g., Nigeria orders)
* Expansion (Dubai, India, etc.) ([GlobeNewswire][3])

BUT:

* Market cap is ~**$500K** ([Yahoo Finance][4])
* Revenue is extremely small relative to losses ([Simply Wall St][5])
* Stock is down ~**-97%+ long term** ([Simply Wall St][5])

👉 Translation:
This is **deep microcap / survival-mode territory**.

---

# ⚖️ 4. Why the CEO is quiet (this part matters most)

You asked a very sharp question here.

There are **3 possible reasons** — and honestly, it’s usually a mix:

### (A) Legal / regulatory restrictions

When a company is:

* Not current with filings
* On Expert Market

They often:

* **Limit public statements**
* Avoid forward-looking disclosures

Also:

* They **can’t freely promote the stock** without current filings (SEC risk)

👉 So yes — there *can* be legal pressure to stay quiet.

---

### (B) Structural limitation of the Expert Market

Companies on Expert Market:

* **Can’t post filings on OTCMarkets** directly ([BioSpace][6])
* Must use alternative channels (like their own website)

This reduces visibility and communication flow.

---

### (C) The uncomfortable truth (common in OTC)

A lot of companies in this situation:

* Go **long periods without communication**
* Prioritize survival over shareholder updates
* Sometimes simply **don’t have meaningful progress to report**

👉 In OTC land, this is *very common behavior*, not necessarily illegal.

---

# 🚨 5. Is the CEO failing his duty?

Here’s the honest answer:

* **Legally:**

* He is *not required* to constantly update shareholders like a big public company
* Especially if filings are not current

* **From an investor standpoint:**

* Lack of communication + missed filings = **poor governance**

👉 So:

* Not necessarily illegal
* But definitely **a red flag for investors**

---

# 🧠 6. What to watch going forward

If you’re holding VDRM, the only things that matter now:

### ✅ Positive signals

* Filing **current financials**
* Moving off Expert Market (back to OTC Pink Current)
* Verified revenue growth (not just PRs)

### 🚩 Negative signals

* Continued silence
* No filings for extended periods
* More “PR-style” updates without hard numbers

---

# 🧾 Bottom line

* VDRM is **not fully dead**, but it’s in a **very weak regulatory and financial position**
* The “delisting” you’re seeing is really:
? **Loss of reporting compliance ? Expert Market downgrade**
* CEO silence is:
? **Partly legal / structural**
? **Partly typical OTC behavior**
? **And possibly lack of progress**

---

If you want, I can dig into **share structure, dilution history, or red flags in management behavior** — that’s usually where the real story shows up with stocks like this.

[1]: https://www.gurufocus.com/news/2907480/viaderma-inc-confirms-ongoing-operations-and-commitment-to-regulatory-compliance-vdrm-stock-news?utm_source=chatgpt.com "ViaDerma, Inc. Confirms Ongoing Operations and ..."
[2]: https://www.nasdaq.com/market-activity/stocks/vdrm/sec-filings?utm_source=chatgpt.com "ViaDerma Inc (VDRM) SEC Filings"
[3]: https://www.globenewswire.com/search/organization/ViaDerma%2520Licensing?utm_source=chatgpt.com "Latest News and Press Releases"
[4]: https://finance.yahoo.com/quote/VDRM/?utm_source=chatgpt.com "ViaDerma, Inc. (VDRM) Stock Price, News, Quote & History"
[5]: https://simplywall.st/stocks/us/pharmaceuticals-biotech/otc-vdrm/viaderma?utm_source=chatgpt.com "ViaDerma (OTCPK:VDRM) - Stock Analysis"
[6]: https://www.biospace.com/press-releases/viaderma-announces-posting-of-annual-report-and-ongoing-evaluation-of-public-status-in-response-to-market-changes?utm_source=chatgpt.com "ViaDerma Announces Posting of Annual Report and ..."

For what its worth, I asked AI to analize the job posting in light of other factors:

On one hand, companies that are truly dead or preparing to disappear usually do not:

* hire junior analysts,
* invest in operational infrastructure,
* maintain ecommerce/web operations,
* build dashboards and reporting systems,
* coordinate inventory/distribution,
* or continue external marketing and podcast appearances.

The posting suggests ViaDerma is still functioning operationally and trying to build internal business processes. The emphasis on PowerBI, Tableau, SQL, Asana, QuickBooks, inventory management, and KPI tracking looks like a company attempting to professionalize operations rather than simply abandon the business.

There are also still visible signs of life publicly:

* active corporate website,
* ongoing SkinPass/VitaStem promotion,
* podcast appearances by management,
* international distribution messaging,
* references to donations/NGO initiatives,
* and public statements in 2025 about continuing operations and working toward compliance. ([InvestorsHub][1])

However — and this is the important distinction — operational activity is not the same thing as shareholder-friendly execution. That is where the bearish case becomes stronger. The major issue is that nearly all observable progress has been:

* commercial,
* promotional,
* operational,
* or aspirational,

while the actual securities/compliance side has remained largely unresolved.

The biggest red flags remain:

1. Prolonged Expert Market status
A year on the Expert Market is extremely damaging for credibility. The longer a company remains there, the harder it becomes to maintain shareholder confidence because:

* liquidity disappears,
* retail participation collapses,
* transparency declines,
* and management communication often deteriorates.

The silence itself becomes part of the problem.

2. Lack of concrete uplisting milestones
I could not find evidence that ViaDerma:

* became current with OTC reporting,
* entered OTCID,
* restored public quotation,
* secured audited filings sufficient for higher-tier OTC status,
* or provided a definitive roadmap with dates. ([InvestorsHub][1])

That absence matters more than podcasts or hiring announcements.

3. “Evaluating strategic options related to its public status”. That language from 2025 is subtle but important.

Companies use wording like that when:

* considering restructuring,
* reducing reporting burdens,
* merging,
* recapitalizing,
* or potentially going dark/private.

It does not prove they are going private — but it absolutely opens the door to the possibility.

4. Chronic overpromising history
You mentioned this yourself, and that’s probably the core issue.

ViaDerma has historically produced:

* many announcements,
* large opportunity narratives,
* international expansion stories,
* licensing/distribution updates,
* future revenue potential,
without corresponding shareholder value realization.

Eventually investors stop reacting to announcements and start demanding audited execution. That appears to be where sentiment is now. My overall assessment:

I do not think ViaDerma currently looks like a completely abandoned shell.

It appears more likely that:

* the business itself is still alive,
* management is still trying to commercialize products,
* and some operational growth efforts are real.

But I also do not think there is strong evidence yet of a disciplined, shareholder-focused path back to normal market status. Right now the company looks caught between two realities:

Operationally alive but Capital-markets dysfunctional. That is a dangerous middle ground for public shareholders. As for your fear about going private:

* I do not see hard evidence that this is imminent.
* But I also cannot dismiss the concern because management’s communication pattern and “strategic options” language leave the possibility open.

The key thing I would watch now is not more podcasts or hiring posts. I would watch for one of these:

* audited/current filings,
* OTC compliance milestones,
* restored quotation capability,
* institutional financing,
* transparent shareholder communication,
* or a definitive restructuring announcement.

Without one of those, operational “signs of life” may continue while shareholders remain trapped in illiquidity.

And psychologically, that’s probably why the silence feels so deafening: investors can see activity, but not progress on the thing that actually matters to shareholders — market accessibility and trust.

Read below V V V Walgreens and CVS are undergoing massive, long-term restructuring, closing thousands of stores due to overexpansion, low reimbursement rates from insurers, high theft, and competition from online retailers. Walgreens plans to close 1,200 stores and CVS is wrapping up a 900-store closure plan, causing "pharmacy deserts" and shifting to smaller, health-focused, or online models.

I'm sure hundreds will apply for that hoax

Just saw this on the website:
Junior Business Analysts

ViaDerma, Inc. in Las Vegas, Nevada is looking for Junior Business Analysts. Qualified candidates will be responsible for conducting market research to identify trends, opportunities, and competitive landscape within the topical antibiotic market;

If only there were signs earlier on

No time Hard day at the water park with famliy